Triple-Attack CAR-T cells take aim at stubborn neuroblastoma
NCT ID NCT04637503
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This clinical trial tests a new type of immunotherapy called 4SCAR-T, which uses a patient's own immune cells engineered to recognize and attack three different markers (GD2, PSMA, and CD276) on neuroblastoma cancer cells. The study enrolls children and adults (ages 1 to 65) with neuroblastoma that has come back or not responded to standard treatments. The goal is to see if this multi-targeted approach is safe and can shrink tumors or slow disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GD2, PSMA and CD276 CAR-T cells
- What this could lead to
- If successful, this approach could offer a new treatment option for children and adults with hard-to-treat neuroblastoma, potentially improving disease control and survival.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome or neurological issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-Immune Medical Institute
RECRUITINGShenzhen, Guangzhou, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a shorter chemo combo tame High-Risk neuroblastoma?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- Can AI read tumor slides to outsmart childhood cancer?
- Can a radioated molecule shrink untreatable neuroblastoma?
- Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma